Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.71 USD
Change Today +0.17 / 3.74%
Volume 83.7K
As of 8:10 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

bind therapeutics inc (BIND) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/9/14 - $10.78
52 Week Low
08/3/15 - $4.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIND THERAPEUTICS INC (BIND)

Related News

No related news articles were found.

bind therapeutics inc (BIND) Related Businessweek News

No Related Businessweek News Found

bind therapeutics inc (BIND) Details

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company, develops various targeted and programmable therapeutics. It is developing Accurins that are designed with specific pharmaceutical characteristics intended to target tumors at tissue, cellular, and molecular levels and to result in superior patient outcomes by enhancing the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue. The company’s lead drug candidate includes BIND-014, a prostate-specific membrane antigen (PSMA) targeted Accurin that contains docetaxel, which is in Phase II clinical trials for non-small cell lung cancer. It is also developing BIND-510, a PSMA-targeted Accurin drug candidate containing the potent microtubule inhibitor vincristine. It has collaboration agreements to develop Accurins based on therapeutic payloads from their product pipelines with Amgen, Inc.; Pfizer Inc.; AstraZeneca AB; Hoffmann-La Roche Ltd.; and Merck & Co. The company was formerly known as BIND Biosciences, Inc. and changed its name to BIND Therapeutics, Inc. in April 2013. BIND Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

89 Employees
Last Reported Date: 03/11/15
Founded in 2006

bind therapeutics inc (BIND) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $334.9K
Chief Medical Officer
Total Annual Compensation: $84.2K
Compensation as of Fiscal Year 2014.

bind therapeutics inc (BIND) Key Developments

BIND Therapeutics Inc. Announce FDA Authorizes Use of AstraZeneca's Accurin AZD2811 in Clinical Trials

BIND Therapeutics Inc. announced the U.S. FDA has authorized the use of AstraZeneca's Accurin AZD2811 in clinical trials under an investigational new drug application. BIND Therapeutics is collaborating with AstraZeneca on the development of AZD2811, an Aurora B Kinase inhibitor that has been shown to be active in both solid and hematological tumors in preclinical models.

BIND Therapeutics Appoints Andrew Hirsch as President and Chief Executive Officer

BIND Therapeutics, Inc. announced that Andrew Hirsch has been appointed president and chief executive officer of the Company. Mr. Hirsch had been serving in the role on an acting basis since March 2015. Mr. Hirsch has also been elected to BIND’s Board of Directors.

BIND Therapeutics, Inc. and Macrophage Therapeutics Announce Collaboration to Engineer CD206 Targeted Accurin Nanoparticle Using Manocept Macrophage Targeting Platform

BIND Therapeutics, Inc. and Macrophage Therapeutics announced they have entered into a research collaboration to engineer Accurins with the Manocept targeting platform that enables selective, efficient binding to CD206 positive disease-associated macrophages. Upon achievement of proof-of-concept, the companies anticipate expanding the collaboration to develop Manocept-linked Accurins as a novel, potent approach to impact the tumor microenvironment which, in many forms of cancer, is a barrier to immune effector cells. Disease-associated macrophages generally play a pro-tumoral role and are immunosuppressive, preventing the immune system from mounting an attack on tumor cells. Based on the expression of CD206 mannose receptors on disease-associated macrophages, BIND and Macrophage plan to conduct joint research to develop a CD206 targeted Accurin nanoparticle that is capable of concentrating various therapeutic payloads to the tumor microenvironment.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIND:US $4.71 USD +0.17

BIND Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIND.
View Industry Companies

Industry Analysis


Industry Average

Valuation BIND Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.0x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIND THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at